Disc Medicine

Disc Medicine is applying new insights in heme biosynthesis and iron metabolism to develop first-in-class therapies for #hematologic diseases.

[Disc Medicine @DiscMedicine]

Today, Disc presents updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis at the @ASCO Annual Meeting. Read more: https://t.co/37CealMaBW

[Disc Medicine @DiscMedicine]

Today, Disc announced the launch of an expanded access program for bitopertin for eligible patients with EPP and XLP in the U.S. Read more: https://t.co/kbtovb7XpC

[Disc Medicine @DiscMedicine]

As #GlobalPorphyriaDay comes to a close, we want to extend our sincere thanks to the advocacy organizations, patients, families, and healthcare providers who continue to shape progress for people living with porphyrias like EPP and XLP.

[Disc Medicine @DiscMedicine]

Today, we recognize #GlobalPorphyriaDay, a moment to raise awareness of the porphyria community and the people impacted. At Disc, we’re committed to advancing understanding of EPP, including XLP. Visit https://t.co/EdYkJ7uPle for resources and to learn more.

[Disc Medicine @DiscMedicine]

What happens when avoiding pain also means avoiding everyday life? EPP and XLP extend beyond physical symptoms, shaping daily life in profound ways. At Disc, we focus on the full burden of rare diseases.

[Disc Medicine @DiscMedicine]

EPP isn’t just a skin condition, it can affect the liver. PPIX builds up, disrupts bile flow, and can lead to complications. At Disc, we’re focused on EPP as a systemic disease. On May 18, #GlobalPorphyriaDay highlights why it’s more than what you can see.

[Disc Medicine @DiscMedicine]

In EPP, phototoxic reactions aren't just immediate, they can be severe and prolonged. The impact goes beyond the skin, affecting sleep, focus, and daily functioning. Learn more from Ginger, who shares her experience living with these reactions as #GlobalPorphyriaDay approaches.

[Disc Medicine @DiscMedicine]

For people living with EPP, life often requires careful planning around light exposure. Global Porphyria Day on May 18 highlights the realities of living with porphyrias and why greater awareness is so important. Hear from Becky about what EPP looks like in her day-to-day life.

[Disc Medicine @DiscMedicine]

EPP isn’t just light sensitivity, it’s pain triggered by light. Even brief exposure can cause intense burning or itching within minutes. It can affect nearly every part of life. Watch below to understand the impact of EPP on daily life ahead of #GlobalPorphyriaDay on May 18.

[Disc Medicine @DiscMedicine]

What’s really driving symptoms in EPP? It’s a molecule called protoporphyrin IX (PPIX, “PP-nine”). In EPP, PPIX builds up and is the underlying cause of disease. As #GlobalPorphyriaDay approaches, it’s a moment to raise awareness of porphyrias. Learn more: https://t.co/HHHB9h72le

[Disc Medicine @DiscMedicine]

Next month, Disc will present updates across our portfolio at the @EHA_Hematology Annual Congress! Read more about EHA 2026: https://t.co/bagd2bT72v

[Disc Medicine @DiscMedicine]

At Disc, our focus on porphyrias is year-round, and as #GlobalPorphyriaDay approaches on May 18, we are expanding the conversation. In the days ahead, we’ll share more about EPP and XLP – rare, genetically driven hematologic diseases. Stay tuned!

[Disc Medicine @DiscMedicine]

Today we reported our Q1 financials and operational progress. Together, these milestones highlight strong execution and position us for multiple catalysts in the second half of the year: https://t.co/UGFqmNx9GP

[Disc Medicine @DiscMedicine]

On June 2, Disc will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis in an oral abstract session at the @ASCO Annual Meeting. Learn more: https://t.co/T4ZaGnCR8D

[Disc Medicine @DiscMedicine]

We’re on the ground at AAD 2026! Visit booth #4155 to connect with our team and explore progress in EPP research. And don’t miss our disease state education theater on March 27th at 11:15am in Theater 2.

[Disc Medicine @DiscMedicine]

We’re thrilled to share that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Thank you to the patients, families, investigators, and study teams who made this milestone possible. Read more: https://t.co/SVdDQeSqkL

[Disc Medicine @DiscMedicine]

Disc is heading to the 2026 AAD Annual Meeting next week! Visit booth #4155 to learn the latest on bitopertin for EPP and connect with our team. We can’t wait to engage with the dermatology community!

[Disc Medicine @DiscMedicine]

On Rare Disease Day, we remember the people and families behind every diagnosis. At Disc, we’re committed to advancing therapies for rare hematologic diseases and delivering impact to patients.

Learn more at https://t.co/FgKGqTyAPm and explore Disc at https://t.co/pR0kxDZbbz

[Disc Medicine @DiscMedicine]

Today we reported our fourth quarter and full-year 2025 financial results and shared recent program and corporate updates. Read more about our progress in bitopertin, DISC-0974, and DISC-3405 in the latest press release: https://t.co/8NBXp5L1f0

[Disc Medicine @DiscMedicine]

We’re pleased to welcome Lisa Amaya Price as our Chief HR Officer! With 25+ years of experience in HR and organizational leadership, Lisa will play a critical role as we advance our mission to develop new medicines for blood-based diseases. Learn more: https://t.co/xomeEEqkDV